about
Adaptive resistance to therapeutic PD-1 blockade is associated with upregulation of alternative immune checkpoints.Image-guided radiotherapy platform using single nodule conditional lung cancer mouse modelsGenomewide discovery and classification of candidate ovarian fertility genes in the mouseSomatic LKB1 mutations promote cervical cancer progression.Multiple interaction domains in FtsL, a protein component of the widely conserved bacterial FtsLBQ cell division complex.Loss of Lkb1 and Pten leads to lung squamous cell carcinoma with elevated PD-L1 expressionKinase domain activation of FGFR2 yields high-grade lung adenocarcinoma sensitive to a Pan-FGFR inhibitor in a mouse model of NSCLCCooperation between p53 and the telomere-protecting shelterin component Pot1a in endometrial carcinogenesis.Targeting transcriptional addictions in small cell lung cancer with a covalent CDK7 inhibitorDifferential roles of telomere attrition in type I and II endometrial carcinogenesis.Efficacy of BET bromodomain inhibition in Kras-mutant non-small cell lung cancer.The impact of the MYB-NFIB fusion proto-oncogene in vivo.D-2-hydroxyglutarate produced by mutant IDH2 causes cardiomyopathy and neurodegeneration in mice.Co-clinical trials demonstrate superiority of crizotinib to chemotherapy in ALK-rearranged non-small cell lung cancer and predict strategies to overcome resistance.STK11/LKB1 Deficiency Promotes Neutrophil Recruitment and Proinflammatory Cytokine Production to Suppress T-cell Activity in the Lung Tumor Microenvironment.Development of Selective Covalent Janus Kinase 3 Inhibitors.Interleukin-17A Promotes Lung Tumor Progression through Neutrophil Attraction to Tumor Sites and Mediating Resistance to PD-1 Blockade.Activation of the PD-1 pathway contributes to immune escape in EGFR-driven lung tumors.Lkb1 inactivation drives lung cancer lineage switching governed by Polycomb Repressive Complex 2.Erratum: Lkb1 inactivation drives lung cancer lineage switching governed by Polycomb Repressive Complex 2.JAK2/IDH-mutant-driven myeloproliferative neoplasm is sensitive to combined targeted inhibition.Co-clinical quantitative tumor volume imaging in ALK-rearranged NSCLC treated with crizotinib.Clinical implications of monitoring nivolumab immunokinetics in non-small cell lung cancer patientsCorrigendum: Mutant IDH inhibits HNF-4α to block hepatocyte differentiation and promote biliary cancerJAK2/IDH-mutant-driven myeloproliferative neoplasm is sensitive to combined targeted inhibitionAutochthonous murine models for the study of smoker and never-smoker associated lung cancersSuppression of Myeloid Cell Arginase Activity leads to Therapeutic Response in a NSCLC Mouse Model by Activating Anti-Tumor ImmunityPolymerase-mediated ultramutagenesis in mice produces diverse cancers with high mutational load.Assessing Therapeutic Efficacy of MEK Inhibition in a KRASG12C-Driven Mouse Model of Lung CancerIdentification and characterization of an alternative cancer-derived PD-L1 splice variantDysfunctional telomeres trigger cellular senescence mediated by cyclic GMP-AMP synthase
P50
Q27853339-CF7E0C53-E7B6-409C-94CB-E82B1D9225BDQ30610005-D5F9FE76-7AD6-41EE-B879-027A7D07636BQ33292133-7D13E861-A7BF-486D-A7E7-8FA968B8E72BQ33425903-1ECE7B62-2F98-49BF-9E33-F142E0B44D18Q33876882-1C9628E4-BDCC-4D80-85E1-E7C4496801FBQ33956097-22774EB2-648E-43D8-A55F-5EE5F17D6BD6Q34135320-36704D30-A353-44BD-A592-6A90607E6ACEQ34300546-39C9D97E-5171-44A0-A74A-79079CC60813Q34452854-99FAEDAC-ABAD-427D-972E-0E6FEB9DD6A3Q36778280-3D184183-DEF7-4589-A265-1BA489D5AC91Q37338486-6E45AF45-A038-4D69-A8B1-8C624AE5F3A9Q37362488-9AFB96B1-3540-41D4-A59C-6EBDFB0532BBQ37631229-2883BFCC-D74B-44C3-BAF2-DB9084DC45B2Q38194999-078983D4-2BE6-47FD-BD62-207443851EBDQ38731119-86DECAB4-D8D5-44F0-81D8-AFBE579DE1ACQ38763094-155A811D-BC64-4A08-B592-1E5C6248F696Q38797202-19CF7A3A-FE55-439C-879D-D9A95693B02AQ39089944-B2C07D45-05BE-4576-A672-3E5F0FE83DADQ41819380-9AE01A44-BF7A-4569-B2A9-F4B62452E372Q42338060-90B446A0-8F2F-4AB1-8B75-5A857C59408BQ49659982-FE757BA2-E890-4226-AC8F-4943F710CEB2Q50898344-FE09DCCE-8626-4035-BD49-1268A7A5C1D5Q57029319-66C1B584-4728-4921-8377-8CDC58D3EC8EQ57756438-09002D97-36AE-43B2-8AD6-28120B47EFB8Q58730676-021B9DD2-9984-4603-8D60-47301F88F13AQ58804389-8A7F4202-3BA5-47E1-A387-1A0EE78A9203Q61798869-A0F2446C-878E-4A78-B1F5-01E4C3E2F6EBQ64997686-470CDD26-7313-4D06-B162-68B45411CD3EQ89266805-A13F582F-025F-4A7A-9970-5260BD9F2B3CQ90626079-82225E0E-A0E7-4781-9776-974BC383DEF6Q96429353-8F1E6594-74E5-491A-A5F8-33AC03BB2477
P50
description
researcher ORCID ID = 0000-0002-4149-2529
@en
wetenschapper
@nl
name
Esra A Akbay
@ast
Esra A Akbay
@en
Esra A Akbay
@es
Esra A Akbay
@nl
type
label
Esra A Akbay
@ast
Esra A Akbay
@en
Esra A Akbay
@es
Esra A Akbay
@nl
prefLabel
Esra A Akbay
@ast
Esra A Akbay
@en
Esra A Akbay
@es
Esra A Akbay
@nl
P1153
22333707500
P31
P496
0000-0002-4149-2529